How AI is set to disrupt pharma IP business models

Increasing numbers of patent applications prove that AI is having a profound impact on the pharmaceutical industry. BenevolentAI’s Gareth Jones identifies numerous arguments for and against amending inventorship rules

Enter your details below to log into your account.

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.

Gareth Jones

Vice president of intellectual property | BenevolentAI

Twitter

08 Aug 2020

@IAM_magazine China will play a huge role in shaping the future of video compression technology - and the way the IP surrounding… https://t.co/uCbU0we9aC Read more

07 Aug 2020

@IAM_magazine Who will grant first? “Defendants’ position is anti-intellectual property and anti-business, and it puts American b… https://t.co/CTDQnid2hc Read more

07 Aug 2020

@IAM_magazine RPX picks up patent portfolio from failed AR biz as defensive player makes largest acquisition in years… https://t.co/qvh9Mz49HI Read more

07 Aug 2020

@IAM_magazine Intel is a major patent force and that matters https://t.co/UbXGYnxjTZ https://t.co/uGRNWPcRAA Read more